{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:13Z","timestamp":1792790473277,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Histiocytic neoplasms with xanthogranulomatous morphology encompass a continuum of disorders\u2014from isolated cutaneous juvenile xanthogranuloma (JXG) or adult xanthogranuloma (AXG) to the multisystem Erdheim-Chester disease (ECD)\u2014that share overlapping histopathologic and molecular features. In this article, we (1) define the spectrum of xanthogranuloma lesions, highlighting morphologic and immunohistochemical commonalities; (2) examine the clinical and radiographic criteria that distinguish localized juvenile xanthogranuloma\/adult xanthogranuloma from classical Erdheim-Chester disease and related entities; (3) review the latest insights into MAPK pathway alterations that blur traditional diagnostic boundaries; and (4) outline contemporary management strategies, including approaches to staging \u201coccult\u201d disease, patient selection for BRAF and MEK inhibitors, and the role of other targeted and nontargeted agents. Readers will gain practical frameworks for recognizing early or atypical presentations, integrating molecular testing into routine practice, and optimizing personalized therapy across the xanthogranuloma family.<\/jats:p>","DOI":"10.1182\/hematology.2025000706","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:07:58Z","timestamp":1764943678000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["The xanthogranuloma family of histiocytic neoplasms in the molecular era: Erdheim-Chester disease and beyond"],"prefix":"10.1182","volume":"2025","author":[{"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[{"name":"1 Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"2 Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"5","key":"2025120616323820500_hem2025000706C1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","article-title":"Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations","volume":"27","author":"Dehner","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"2025120616323820500_hem2025000706C2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2025120616323820500_hem2025000706C3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamadermatol.2025.0886","article-title":"Clinical, histopathologic, and molecular features and treatment of multiple xanthogranuloma in adults","volume":"161","author":"Annabi","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2025120616323820500_hem2025000706C4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/ajm.ajm_177_19","article-title":"Xanthoma disseminatum with extensive respiratory involvement effectively treated with cladribine: a case report","volume":"10","author":"Al-Tarcheh","year":"2020","journal-title":"Avicenna J Med"},{"issue":"12","key":"2025120616323820500_hem2025000706C5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"2025120616323820500_hem2025000706C6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.18422","article-title":"Classical and non-classical phenotypes of Erdheim-Chester disease: correlating clinical, radiographic and genotypic findings","volume":"199","author":"Hazim","year":"2022","journal-title":"Br J Haematol"},{"issue":"22","key":"2025120616323820500_hem2025000706C7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"issue":"13","key":"2025120616323820500_hem2025000706C8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2023020569","article-title":"Childhood-onset Erdheim- Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients","volume":"142","author":"Pegoraro","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025120616323820500_hem2025000706C9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025120616323820500_hem2025000706C10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025120616323820500_hem2025000706C11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.6004\/jnccn.2021.0053","article-title":"Histiocytic Neoplasms, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Go","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2025120616323820500_hem2025000706C12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.19462","article-title":"Mixed histiocytic neoplasms: a multicentre series revealing diverse somatic mutations and responses to targeted therapy","volume":"205","author":"Friedman","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120616323820500_hem2025000706C13","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2019.216937","article-title":"Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1","volume":"105","author":"Razanamahery","year":"2020","journal-title":"Haematologica"},{"key":"2025120616323820500_hem2025000706C14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2147\/CCID.S375995","article-title":"Successful treatment of non-Langerhans cell histiocytosis with topical rapamycin in two pediatric cases","volume":"15","author":"Effendi","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"2025120616323820500_hem2025000706C15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/pde.15579","article-title":"Oral sirolimus for the treatment of juvenile xanthogranuloma: report of two pediatric cases","volume":"41","author":"Toker","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2025120616323820500_hem2025000706C16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jdcr.2024.03.018","article-title":"Treatment of periorbital xanthogranuloma with fractional carbon dioxide laser","volume":"48","author":"Benson","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"6","key":"2025120616323820500_hem2025000706C17","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/bjd.17032","article-title":"Image gallery: cutaneous lesions of Erdheim-Chester disease treated with carbon dioxide laser therapy","volume":"179","author":"Elosua-Gonz\u00e1lez","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"2025120616323820500_hem2025000706C18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0019-5154.80416","article-title":"Multiple generalized xanthogranuloma in adult: case report and treatment","volume":"56","author":"Achar","year":"2011","journal-title":"Indian J Dermatol"},{"key":"2025120616323820500_hem2025000706C19","first-page":"65","article-title":"Juvenile xanthogranuloma: case report and literature review","volume":"13","author":"Vahabi-Amlashi","year":"2020","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"2025120616323820500_hem2025000706C20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000089027","article-title":"Multiple adult xanthogranuloma: case report and literature review","volume":"212","author":"Saad","year":"2006","journal-title":"Dermatology"},{"issue":"7749","key":"2025120616323820500_hem2025000706C21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"3","key":"2025120616323820500_hem2025000706C22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600- mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"2025120616323820500_hem2025000706C23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41375-025-02526-5","article-title":"Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants","volume":"39","author":"Acosta-Medina","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"2025120616323820500_hem2025000706C24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.18964","article-title":"Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms","volume":"203","author":"Reiner","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120616323820500_hem2025000706C25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13023-018-0988-y","article-title":"Clinical and positron emission tomography responses to long-term high-dose interferon-\u03b1 treatment among patients with Erdheim-Chester disease","volume":"14","author":"Niu","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2025120616323820500_hem2025000706C26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2017.0041","article-title":"Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease","volume":"3","author":"Goyal","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025120616323820500_hem2025000706C27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ajh.26441","article-title":"Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease","volume":"97","author":"Abeykoon","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2025120616323820500_hem2025000706C28","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"E-L","year":"2014","journal-title":"Blood"},{"key":"2025120616323820500_hem2025000706C29","doi-asserted-by":"crossref","first-page":"672547","DOI":"10.3389\/fped.2021.672547","article-title":"Clinical analysis of pediatric systemic juvenile xanthogranulomas: a retrospective single-center study","volume":"9","author":"Lian","year":"2021","journal-title":"Front Pediatr"},{"issue":"1","key":"2025120616323820500_hem2025000706C30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40478-019-0811-6","article-title":"BRAF V600E mutation in juvenile xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease","volume":"7","author":"Picarsic","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"2025120616323820500_hem2025000706C31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.24772","article-title":"Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease","volume":"61","author":"Simko","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2025120616323820500_hem2025000706C32","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2024015399","article-title":"Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study","volume":"9","author":"Pegoraro","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"2025120616323820500_hem2025000706C33","doi-asserted-by":"crossref","first-page":"e1380","DOI":"10.1111\/jdv.19321","article-title":"The association between juvenile xanthogranulomas in neurofibromatosis type 1 patients and the development of leukaemia: a systematic review","volume":"37","author":"Meyer","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2025120616323820500_hem2025000706C34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamaoncol.2025.0011","article-title":"Risk of second cancer in Erdheim-Chester disease","volume":"11","author":"Pegoraro","year":"2025","journal-title":"JAMA Oncol"},{"issue":"2","key":"2025120616323820500_hem2025000706C35","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.3324\/haematol.2019.234187","article-title":"Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2025120616323820500_hem2025000706C36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","article-title":"Treatment of Erdheim-Chester disease with long-term high-dose interferon-\u03b1","volume":"41","author":"Hervier","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2025120616323820500_hem2025000706C37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-022-02193-0","article-title":"Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis","volume":"17","author":"Liu","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"2025120616323820500_hem2025000706C38","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood.2024028032","article-title":"Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease","volume":"145","author":"Goyal","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2025120616323820500_hem2025000706C39","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1210\/clinem\/dgae827","article-title":"Approach to the patient: from endocrinopathy to the diagnosis of a histiocytic disorder","volume":"110","author":"Makras","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/199\/2470473\/199goyal.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/199\/2470473\/199goyal.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:32:48Z","timestamp":1765056768000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/199\/556865\/The-xanthogranuloma-family-of-histiocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000706","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}